NSE - Delayed Quote INR
Themis Medicare Limited (THEMISMED.NS)
133.54
-4.99
(-3.60%)
At close: April 25 at 3:29:57 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
4,264,991
3,766,324
3,444,550
3,913,480
2,293,325
Cost of Revenue
1,536,711
1,397,601
1,209,968
1,519,946
805,330
Gross Profit
2,728,280
2,368,723
2,234,582
2,393,534
1,487,995
Operating Expense
2,191,524
1,976,134
1,665,021
1,531,982
1,078,527
Operating Income
536,756
392,589
569,561
861,552
409,468
Net Non Operating Interest Income Expense
-89,114
-85,373
-90,171
-81,690
-123,004
Pretax Income
595,508
534,432
725,149
952,620
413,307
Tax Provision
134,102
99,197
156,141
223,813
56,278
Net Income Common Stockholders
461,410
435,238
569,010
728,808
357,030
Diluted NI Available to Com Stockholders
461,407
435,235
569,008
728,808
357,030
Basic EPS
5.01
4.73
6.18
7.92
3.89
Diluted EPS
5.00
4.72
6.17
7.91
3.88
Basic Average Shares
92,113.59
92,040.12
92,027.70
92,002.70
91,884.54
Diluted Average Shares
92,268.09
92,205.73
92,180.11
92,175.35
91,914.23
Rent Expense Supplemental
--
21,692
18,077
9,794
8,338
Total Expenses
3,728,235
3,373,735
2,874,989
3,051,928
1,883,857
Net Income from Continuing & Discontinued Operation
461,410
435,238
569,010
728,808
357,030
Normalized Income
460,710.35
434,502.61
568,594.91
728,548.65
356,867.60
Interest Income
--
8,393
5,473
6,055
4,121
Interest Expense
80,016
76,275
79,902
65,369
109,657
Net Interest Income
-89,114
-85,373
-90,171
-81,690
-123,004
EBIT
675,524
610,707
805,051
1,017,989
522,964
EBITDA
780,049
733,170
909,999
1,112,787
608,435
Reconciled Cost of Revenue
1,536,711
1,397,601
1,209,968
1,519,946
805,330
Reconciled Depreciation
104,525
122,463
104,948
94,798
85,471
Net Income from Continuing Operation Net Minority Interest
461,410
435,238
569,010
728,808
357,030
Total Unusual Items Excluding Goodwill
903
903
529
339
188
Total Unusual Items
903
903
529
339
188
Normalized EBITDA
779,146
732,267
909,470
1,112,448
608,247
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
203.35
167.61
113.91
79.65
25.60
3/31/2021 - 4/2/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BALPHARMA.NS Bal Pharma Limited
107.14
-1.61%
BROOKS.NS Brooks Laboratories Limited
139.83
-5.00%
RPGLIFE.NS RPG Life Sciences Limited
2,244.30
-3.82%
SPARC.NS Sun Pharma Advanced Research Company Limited
149.77
-3.37%
SYNCOMF.NS Syncom Formulations (India) Limited
17.04
-5.18%
ORCHPHARMA.NS Orchid Pharma Limited
808.55
-4.14%
SHILPAMED.NS Shilpa Medicare Limited
680.85
-5.67%
SIGACHI.NS Sigachi Industries Limited
42.84
-5.72%
MOREPENLAB.NS Morepen Laboratories Limited
58.82
-5.46%
WOCKPHARMA.NS Wockhardt Limited
1,397.60
-4.61%